Core Viewpoint - The company emphasizes the importance of being a pioneer rather than a copier, which is central to its strategic planning [1] Group 1: Company Strategy - The company acknowledges that merely following existing research and development will not drive industry progress or create long-term competitive advantages [1] - The core development goal of the company is to address industry pain points and lead technological advancements [1] - The company expresses a desire to collaborate with investors to witness future breakthroughs [1]

Core Viewpoint - The company announced the nomination of Mr. Wang Yongli as a candidate for a non-independent director position during the 19th meeting of the fifth board of directors held on September 23, 2025 [1] Group 1 - The fifth board of directors' 19th meeting was held on September 23, 2025 [1] - The board approved the proposal to elect a non-independent director [1] - Mr. Wang Yongli has been nominated as a candidate for the non-independent director position [1]

北京九强生物技术股份有限公司 关于补选非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 | 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-083 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司（以下简称"公司"）原副董事长、 董事梁红军先生因工作调动原因已辞去公司副董事长、董事、董事会专门 委员会职务。辞去上述职务后，梁红军先生不再担任公司任何职务，其在 公司子公司的任职，已按照有关规定同步办理离职手续，之后不再担任公 司子公司任何职务。具体内容请见公司于 2025 年 9 月 5 日在巨潮资讯网披 露的《关于副董事长、总经理离任的公告》（公告编号：2025-072）。 为保障董事会正常运作，健全董事会决策机制，经持有公司 3%以上股 份的股东中国医药投资有限公司提名，董事会提名委员会资格审查通过， 公司于 2025 年 9 月 23 日召开了第五届董事会第十九次会议，审议通过了 《关于补选非独立董事的议案》，董事会同意提名王永利先生 ...

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-084 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日召开的第五届董事会第十九次会议审议通过了《关于提请召开 2025 年第一 次临时股东大会的议案》，决定于 2025 年 10 月 10 日（星期五）召开公司 2025 年第一次临时股东大会。现将本次股东大会有关事项通知如下： （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 向股东提供网络形式的投票平台，公司股东应在本通知列明的有关时限内通过 深圳证券交易所交易系统或互联网投票系统进行网络投票。 股东只能选择上述投票表决方式中的一种方式。同一表决权出现重复投票 的以第一次有效投票结果为准。 一、召开会议基本情况 1．股东大会届次：2025 年第一次临时股东 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 | 证券代码：300406 | 证券简称：九强生物 公告编号：2025-082 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司(以下简称"公司")第五届董事会第十 九次会议（以下简称"本次会议"）通知于 2025 年 9 月 17 日以电子邮件及 书面方式发出。本次会议于 2025 年 9 月 23 日以现场会议方式在北京市海淀 区花园东路 15 号旷怡大厦 5 层公司会议室召开。由公司董事长邹左军主持， 董事刘希、罗爱平、孙小林、王小亚、陈永宏、杨建平、叶军出席了会议。 公司监事及高级管理人员列席了本次会议。 北京九强生物技术股份有限公司 第五届董事会第十九次会议决议公告 表决结果：8票同意，0票反对，0票弃权。 本议案尚需提交公司2025年第一次临时股东大会审议。 2、审议通过《关于提请召开2025年第一次临时股东大会的议案》 公司拟定于 2025年10月10日(星期五)14:00 在公司会议室（北京市海 淀区花园东 ...

Core Viewpoint - The company, Jiukang Bio, is a leading player in the in vitro diagnostic industry in China, focusing on the research, production, and sales of diagnostic products [1] Group 1: Company Overview - Jiukang Bio is recognized as a national high-tech enterprise [1] - The company offers a range of in vitro diagnostic products that are developed in line with international standards [1] Group 2: Product Offerings - The product portfolio includes pathology detection systems, biochemical detection systems, coagulation detection systems, luminescence detection systems, blood type detection systems, POCT detection systems, and liquid biopsy CTC [1] Group 3: Future Plans - The company indicated that any future developments in innovative drugs will be disclosed in accordance with information disclosure regulations [1]

Core Viewpoint - The company Jiukang Bio (300406.SZ) has received an update regarding the shareholding increase plan from its major shareholder, China National Pharmaceutical Group Investment Co., Ltd. [1] Group 1: Shareholding Increase - As of the announcement date, the shareholding increase plan has passed the halfway mark [1] - China National Pharmaceutical Group has acquired a total of 2,621,000 shares through centralized bidding, representing 0.45% of the company's voting shares [1] - The total amount invested in this share acquisition is approximately 35,696,359 RMB [1]

Core Viewpoint - China Medical Investment Co., Ltd., a major shareholder of Jiukang Bio (SZ 300406), plans to increase its stake in the company by investing at least 30 million RMB from June 23, 2025, to December 22, 2025, through various trading methods [1] Group 1: Shareholder Actions - The major shareholder has already increased its stake by approximately 2.62 million shares, representing 0.45% of the company's voting shares, with an investment amount of about 35.7 million RMB [1] - The increase in shareholding is part of a broader strategy to enhance the company's market position and investor confidence [1] Group 2: Company Financials - Jiukang Bio's revenue for the year 2024 is expected to be entirely derived from the healthcare sector, with a 100% contribution from this segment [1] - As of the announcement date, Jiukang Bio's market capitalization stands at 7.8 billion RMB [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于公司持股 5%以上股东增持公司股份计划实施期限过半的公告 持股 5%以上的股东中国医药投资有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、增持计划的基本情况：持股 5%以上的股东中国医药投资有限公司（以下 简称"国药投资"或"增持主体"）计划自 2025 年 6 月 23 日至 2025 年 12 月 22 日，通过集中竞价交易、大宗交易等法律法规允许的方式增持公司股票，计 划增持公司股份金额不少于 3000 万元（含）人民币（含 2025 年 6 月 23 日已增 持部分），增持所需资金为自有资金。 2、增持实施情况：截至本公告披露日，本次增持计划实施期限已过半。增 持主体以集中竞价交易的方式共增持股份 2,621,000 股，占公司当前有表决权股 份比例 0.4 ...

Core Viewpoint - The company acknowledges the increasing penetration and accelerated technological iteration in the IVD industry, leading to more refined and specialized market competition, while regulatory policies are guiding the industry towards higher quality and compliance [1] Group 1: Industry Trends - The IVD industry is experiencing a gradual increase in penetration rates and rapid technological advancements [1] - Market competition is becoming more refined and specialized due to these changes [1] - Regulatory policies are promoting the industry towards higher quality and compliance [1] Group 2: Company Strategy - The company maintains a clear understanding of the industry dynamics and continues to focus on its core IVD sector [1] - The company is also exploring new directions with strong technological synergies and broad market potential in the medical device field [1] - The company aims to deliver solid performance to reward its investors in the future [1]